These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3961821)

  • 1. The effects of sulindac and its metabolites on acute stress-induced gastric ulcers in rats.
    Glavin GB; Sitar DS
    Toxicol Appl Pharmacol; 1986 Apr; 83(2):386-9. PubMed ID: 3961821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsteroidal anti-inflammatory effect of sulindac sulfoxide and sulfide on gastric mucosa.
    Graham DY; Smith JL; Holmes GI; Davies RO
    Clin Pharmacol Ther; 1985 Jul; 38(1):65-70. PubMed ID: 3874038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dimethyl sulfoxide on sulindac disposition in rats.
    Swanson BN; Mojaverian P; Boppana VK; Dudash MR
    Drug Metab Dispos; 1981; 9(6):499-502. PubMed ID: 6120805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotransformation of sulindac in end-stage renal disease.
    Gibson TP; Dobrinska MR; Lin JH; Entwistle LA; Davies RO
    Clin Pharmacol Ther; 1987 Jul; 42(1):82-8. PubMed ID: 3595070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of graded oral doses of sulindac in man.
    Mattila J; Mäntylä R; Vuorela A; Lamminsivu U; Männistö P
    Arzneimittelforschung; 1984; 34(2):226-9. PubMed ID: 6539116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulfone metabolite of sulindac inhibits mammary carcinogenesis.
    Thompson HJ; Jiang C; Lu J; Mehta RG; Piazza GA; Paranka NS; Pamukcu R; Ahnen DJ
    Cancer Res; 1997 Jan; 57(2):267-71. PubMed ID: 9000566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal metabolism of sulindac: functional implications.
    Miller MJ; Bednar MM; McGiff JC
    J Pharmacol Exp Ther; 1984 Nov; 231(2):449-56. PubMed ID: 6436473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of uremia and anephric state on the pharmacokinetics of sulindac and its metabolites in rats. I. An application of pharmacokinetic model for reversible metabolism.
    Lin JH; Yeh KC; Duggan DE
    Drug Metab Dispos; 1985; 13(5):602-7. PubMed ID: 2865111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis.
    Mahmoud NN; Boolbol SK; Dannenberg AJ; Mestre JR; Bilinski RT; Martucci C; Newmark HL; Chadburn A; Bertagnolli MM
    Carcinogenesis; 1998 Jan; 19(1):87-91. PubMed ID: 9472698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis.
    Piazza GA; Rahm AL; Krutzsch M; Sperl G; Paranka NS; Gross PH; Brendel K; Burt RW; Alberts DS; Pamukcu R
    Cancer Res; 1995 Jul; 55(14):3110-6. PubMed ID: 7606732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enterohepatic circulation of sulindac and metabolites.
    Dujovne CA; Pitterman A; Vincek WC; Dobrinska MR; Davies RO; Duggan DE
    Clin Pharmacol Ther; 1983 Feb; 33(2):172-7. PubMed ID: 6822030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties.
    Kashfi K; Chattopadhyay M; Kodela R
    Redox Biol; 2015 Dec; 6():287-296. PubMed ID: 26298203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process.
    Reddy BS; Kawamori T; Lubet RA; Steele VE; Kelloff GJ; Rao CV
    Cancer Res; 1999 Jul; 59(14):3387-91. PubMed ID: 10416599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of age and disease on the pharmacokinetics and pharmacodynamics of sulindac.
    Sitar DS; Owen JA; MacDougall B; Hunter T; Mitenko PA
    Clin Pharmacol Ther; 1985 Aug; 38(2):228-34. PubMed ID: 4017423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The disposition of sulindac.
    Duggan DE; Hare LE; Ditzler CA; Lei BW; Kwan KC
    Clin Pharmacol Ther; 1977 Mar; 21(3):326-35. PubMed ID: 300048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth.
    Williams CS; Goldman AP; Sheng H; Morrow JD; DuBois RN
    Neoplasia; 1999 Jun; 1(2):170-6. PubMed ID: 10933052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial uncoupling by the sulindac metabolite, sulindac sulfide.
    Leite S; Martins NM; Dorta DJ; Curti C; Uyemura SA; dos Santos AC
    Basic Clin Pharmacol Toxicol; 2006 Oct; 99(4):294-9. PubMed ID: 17040214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of growth arrest and DNA damage-inducible 45alpha expression confers resistance to sulindac and indomethacin-induced gastric mucosal injury.
    Chiou SK; Hodges A; Hoa N
    J Pharmacol Exp Ther; 2010 Sep; 334(3):693-702. PubMed ID: 20498252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and dialyzability of sulindac and metabolites in patients with end-stage renal failure.
    Ravis WR; Diskin CJ; Campagna KD; Clark CR; McMillian CL
    J Clin Pharmacol; 1993 Jun; 33(6):527-34. PubMed ID: 8366178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of sulindac metabolism by dimethyl sulfoxide in the rat.
    Swanson BN; Mojaverian P; Boppana VK
    J Toxicol Environ Health; 1983; 12(2-3):213-22. PubMed ID: 6655731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.